丹黄祛瘀胶囊治疗慢性盆腔炎的药物经济学评价OA

Objective A pharmacoeconomic evaluation of Danhuang Quyu Capsules for the treatment of chronic pelvic inflammatory disease(SPID)was conducted to provide a theoretical reference basis for clinical optimization of drug treatment regimens and rational drug selection.Methods In this study,we construct a model for the treatment of SPID with Danhuang Quyu Capsule from a health system perspective.To calculate the cost of the two intervention regimens with the cost of drugs obtained by querying the Pharmaceutical Intelligence Network and the data derived from searching the literature,and to evaluate the economics of Danghuang Quyu Capsules in combination with antibiotics versus antibiotics alone for the intervention of SPID on the basis of the effect metrics from 1 published meta-analysis,and finally to validate the stability of the incremental cost-effectiveness ratios(ICER)by using sensitivity analyses.Results After 28 days of patient treatment,the effect obtained in the Danhuang Quyu Capsule group was better than the control group,but the cost of use was also higher than the control group,The ICER value for the two groups was 2 324.06,compared with the conventional therapy alone regimen,The use of Danhuang Quyu capsules combined with antibiotics for the treatment of chronic pelvic inflammatory disease requires an additional cost of 2 324.06 yuan for each additional patient's pelvic mass disappearance,with an ICER value less than 16%of our per capita disposable income in 2022.The results of this study were validated by sensitivity analysis to be robust.Conclusion Assuming the latest disposable income per capita data provided by the National Bureau of Statistics for 2023 as the patient's willingness-to-pay threshold,it can be concluded that Danhuang Quyu Capsules combined with antibiotic treatment has economic advantages over antibiotics alone in making pelvic mass disappear in SPID patients.